iTeos Therapeutics, Inc. Board of Directors

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Dr. Michel Detheux Ph.D.

Dr. Michel Detheux Ph.D.

President, CEO & Director

Mr. Philippe Brantegem

Mr. Philippe Brantegem

Executive Vice President of Human Resources

Mr. Matthew Gall

Mr. Matthew Gall

Chief Financial Officer

Mr. Matthew A. Call M.B.A.

Mr. Matthew A. Call M.B.A.

Chief Operating Officer

Ms. Adi Osovsky

Ms. Adi Osovsky

Executive Vice President of Legal

Dr. Yvonne McGrath Ph.D.

Dr. Yvonne McGrath Ph.D.

Chief Scientific Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.